Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antidiabetic drug
thiazolidinedione |
| gptkbp:approvalYear |
1999
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
A10BG03
|
| gptkbp:brand |
gptkb:Actos
Glustin |
| gptkbp:CASNumber |
111025-46-8
|
| gptkbp:contraindication |
heart failure
active bladder cancer |
| gptkbp:discoveredBy |
gptkb:Takeda_Pharmaceuticals
|
| gptkbp:eliminationHalfLife |
3-7 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:hasMolecularFormula |
C19H20N2O3S
|
| https://www.w3.org/2000/01/rdf-schema#label |
Pioglitazone
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
PPARĪ³ agonist
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:proteinBinding |
>99%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
edema
weight gain bone fracture risk heart failure risk bladder cancer risk |
| gptkbp:usedFor |
gptkb:type_2_diabetes_mellitus
|
| gptkbp:bfsParent |
gptkb:Zentiva
|
| gptkbp:bfsLayer |
7
|